A Case of Advanced Biliary Tract Cancer With <i>EGFR</i> Amplification That Responded to Necitumumab
This report supports the clinical benefit of anti-EGFR antibodies for EGFR-amplified biliary tract cancers and the importance of genomic analysis in personalized therapy and drug resistance research.
Authors
- Sho Tsuyuki (ORCID: https://orcid.org/0009-0000-1026-7778)
- Kazuya Sugimori (ORCID: https://orcid.org/0000-0003-1596-0744)
- Shin Maeda (ORCID: https://orcid.org/0000-0002-0246-1594)
- Makoto Sugimori (ORCID: https://orcid.org/0000-0001-5272-5167)
- Kazushi Numata (ORCID: https://orcid.org/0000-0003-4671-4431)
- Chikara Kunisaki (ORCID: https://orcid.org/0000-0002-0843-8766)
- Akito Nozaki (ORCID: https://orcid.org/0000-0002-3310-6632)
- Haruka Hirose (ORCID: https://orcid.org/0009-0007-3827-257X)
- Akane Hirotani (ORCID: https://orcid.org/0000-0002-9188-5187)
- Haruo Miwa (ORCID: https://orcid.org/0000-0001-6324-5433)
- Takashi Kaneko (ORCID: https://orcid.org/0000-0001-9368-1658)
- Masaki Nishimura (ORCID: https://orcid.org/0000-0003-4540-5733)
- Yoshiaki Inayama (ORCID: https://orcid.org/0000-0002-8916-2924)
Institutions
- Yokohama City University Medical Center (JP)
- Yokohama City University (JP)
Publication Details
- Journal
- Cancer Reports
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1002/cnr2.70053
- Citations
- 1
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- Kihara Memorial Yokohama Foundation